Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.58 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 11/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.41 |
| ▸ | HPGD | P15428 | 4/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.41 |
| ▸ | CFTR | P13569 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 3/20 | 0.40 |
| ▸ | GLA | P06280 | 2/20 | 0.40 |
| ▸ | PKM | P14618 | 3/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | STAT3 | P40763 | 1/20 | 0.38 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 3/20 | 0.37 |
| ▸ | TSHR | P16473 | 2/20 | 0.37 |
| ▸ | CASP1 | P29466 | 1/20 | 0.37 |
| ▸ | CASP7 | P55210 | 1/20 | 0.37 |
| ▸ | ATM | Q13315 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL9369833 | 0.98 | TDP1 (0.61) | TDP1NPSR1KDM4EALDH1A1HSD17B10 | |
| SCHEMBL20049786 | 0.80 | TDP1 (0.53) | TDP1KDM4EALDH1A1HSD17B10HPGD | |
| SCHEMBL109707 | 0.78 | NPSR1 (0.46) | TDP1NPSR1KDM4EALDH1A1HSD17B10 | |
| SCHEMBL31319640 | 0.78 | NPSR1 (0.46) | TDP1NPSR1KDM4EALDH1A1HSD17B10 | |
| SCHEMBL12263255 | 0.78 | NPSR1 (0.46) | TDP1NPSR1KDM4EALDH1A1HSD17B10 | |
| SCHEMBL6422368 | 0.77 | NPSR1 (0.45) | TDP1NPSR1KDM4EALDH1A1HSD17B10 | |
| SCHEMBL13469112 | 0.76 | NPSR1 (0.43) | TDP1NPSR1KDM4EALDH1A1HSD17B10 | |
| SCHEMBL9365314 | 0.75 | CA2 (0.46) | TDP1NPSR1KDM4EALDH1A1STAT3 | |
| SCHEMBL15614505 | 0.74 | NPSR1 (0.42) | TDP1NPSR1KDM4EALDH1A1HSD17B10 | |
| SCHEMBL9364889 | 0.72 | NPSR1 (0.39) | TDP1NPSR1KDM4EALDH1A1HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260138956-A1 | NOVEL COMPOUNDS AND USES THEREOF | RECURSION PHARMACEUTICALS INC (US) | 2026-05-21 | — | — | US | disclosed |
| WO-2024081345-A1 | BENZOPYRIMIDIN-4(3H)-ONES AS PI3K INHIBITORS | ONKURE, INC. (US) | 2024-04-18 | — | — | WO | disclosed |
| CN-113423711-B | Thieno [3,2-B ] pyridine derivatives as UDP glycosyltransferase inhibitors and methods of use thereof | 建新公司 | 2024-03-15 | — | — | CN | disclosed |
| US-11878979-B2 | Substituted imidazo[1,2-b]pyridazines, substituted imidazo[1,5-b]pyridazines, related compounds, and their use in the treatment of medical disorders | Bial—R&D Investments, S.A. (PT) | 2024-01-23 | — | — | US | disclosed |
| CN-109311902-B | Substituted imidazo [1,2-b ] pyridazines, imidazo [1,5-b ] pyridazines, related compounds, and uses thereof | BIAL研发投资股份有限公司 | 2022-07-15 | — | — | CN | disclosed |
| US-20220185814-A1 | SUBSTITUTED IMIDAZO[1,2-b]PYRIDAZINES, SUBSTITUTED IMIDAZO[1,5-b]PYRIDAZINES, RELATED COMPOUNDS, AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS | BIAL - R&D INVESTMENTS, S.A. (PT) | 2022-06-16 | — | — | US | disclosed |
| US-20220185814-A1 | SUBSTITUTED IMIDAZO[1,2-b]PYRIDAZINES, SUBSTITUTED IMIDAZO[1,5-b]PYRIDAZINES, RELATED COMPOUNDS, AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS | BIAL - R&D INVESTMENTS, S.A. (PT) | 2022-06-16 | — | — | US | disclosed |
| EP-3523305-B1 | IMIDAZOPYRIDAZINE COMPOUNDS USEFUL AS MODULATORS OF IL-12, IL-23 AND/OR IFN ALPHA RESPONSES | BRISTOL MYERS SQUIBB CO (US) | 2021-12-08 | — | — | EP | disclosed |
| US-11168087-B2 | Substituted imidazo[1,2-b]pyridazines, substituted imidazo[1,5-b]pyridazines, related compounds, and their use in the treatment of medical disorders | Bial—R&D Investments, S.A. (PT) | 2021-11-09 | — | — | US | disclosed |
| US-11168087-B2 | Substituted imidazo[1,2-b]pyridazines, substituted imidazo[1,5-b]pyridazines, related compounds, and their use in the treatment of medical disorders | Bial—R&D Investments, S.A. (PT) | 2021-11-09 | — | — | US | disclosed |
| US-20080312223-A1 | Thiazole And Isothiazole Derivatives That Modulate The Activity Of CDK, GSK And Aurora Kinases | ASTEX THERAPEUTICS LIMITED (GB) | 2008-12-18 | — | — | US | disclosed |
| US-20080167309-A1 | Pharmaceutical Compounds | ASTEX THERAPEUTICS, LTD. (UK) | 2008-07-10 | — | — | US | disclosed |
| US-20080167309-A1 | Pharmaceutical Compounds | ASTEX THERAPEUTICS, LTD. (UK) | 2008-07-10 | — | — | US | disclosed |
| US-20080167309-A1 | Pharmaceutical Compounds | ASTEX THERAPEUTICS, LTD. (UK) | 2008-07-10 | — | — | US | disclosed |
| EP-1836199-A1 | THIAZOLE AND ISOTHIAZOLE DERIVATIVES THAT MODULATE THE ACTIVITY OF CDK, GSK AND AURORA KINASES | Astex Therapeutics Limited (GB) | 2007-09-26 | — | — | EP | disclosed |
| EP-1781647-A2 | THIAZOLE AND ISOTHIAZOLE DERIVATIVES AS PROTEIN KINASE INHIBITORS | Astex Therapeutics Limited (GB) | 2007-05-09 | — | — | EP | disclosed |
| WO-2007028520-A1 | IMINOOXAZOLIDINE DERIVATIVES AND USE THEREOF | BAYER HEALTHCARE AG (DE) | 2007-03-15 | — | — | WO | disclosed |
| WO-2006070192-A1 | THIAZOLE AND ISOTHIAZOLE DERIVATIVES THAT MODULATE THE ACIVITY OF CDK, GSK AND AURORA KYNASES | ASTEX THERAPEUTICS LIMITED (GB) | 2006-07-06 | — | — | WO | disclosed |
| WO-2006070192-A1 | THIAZOLE AND ISOTHIAZOLE DERIVATIVES THAT MODULATE THE ACIVITY OF CDK, GSK AND AURORA KYNASES | ASTEX THERAPEUTICS LIMITED (GB) | 2006-07-06 | — | — | WO | disclosed |
| WO-2006008545-A2 | THIAZOLE AND ISOTHIAZOLE DERIVATIVES AS PROTEIN KINASE INHIBITORS | ASTEX THERAPEUTICS LIMITED (GB) | 2006-01-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260138956-A1 | NOVEL COMPOUNDS AND USES THEREOF | SLC10A1, NR3C2, CYP2C8 | TDP1 2843/4885NPSR1 339/4885KDM4E 4053/4885 |
| US-11168087-B2 | Substituted imidazo[1,2-b]pyridazines, substituted imidazo[1,5-b]pyridazines, related compounds, and their use in the treatment of medical disorders | GBA1, GBA2, GALC | TDP1 176/4885NPSR1 3399/4885KDM4E 861/4885 |
| US-11878979-B2 | Substituted imidazo[1,2-b]pyridazines, substituted imidazo[1,5-b]pyridazines, related compounds, and their use in the treatment of medical disorders | GBA1, GBA2, GALC | TDP1 176/4885NPSR1 3399/4885KDM4E 861/4885 |
| US-20080312223-A1 | Thiazole And Isothiazole Derivatives That Modulate The Activity Of CDK, GSK And Aurora Kinases | CDK1, CDK8, CDK2 | TDP1 1583/4885NPSR1 3752/4885KDM4E 737/4885 |
| US-20220185814-A1 | SUBSTITUTED IMIDAZO[1,2-b]PYRIDAZINES, SUBSTITUTED IMIDAZO[1,5-b]PYRIDAZINES, RELATED COMPOUNDS, AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS | GBA1, GBA2, GALC | TDP1 176/4885NPSR1 3399/4885KDM4E 861/4885 |
| US-20080167309-A1 | Pharmaceutical Compounds | CCNO, CDK2, CDK1 | TDP1 3003/4885NPSR1 990/4885KDM4E 1029/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.